Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration

Inclusion Criteria

• •1. Received intravitreal antiangiogenic therapy for CNV in the study eye (SE), within 2-12 months prior to the study
• •2. Last diagnosis was, and current diagnosis is, no CNV activity in SE eye
• •3. Current plan in SE is clinical examination as standard care but at intervals of not more than 8 weeks.
• •4. Visual acuity of 20/80 or better in SE
• •5. Are capable and agree to sign a consent form and participate in the study
• •6. Age \> 55 year of age
• •7. Are able to use a standard computer mouse correctly and without assistance
• •8. Have a working telephone landline at the main residence (cellular communication maybe available for the study, and then eliminate this requirement)
• •9. Clear view of the macular area on fundus photography
• •10. Are willing to give their name and contact information to Notal Vision, supplier of the device, so that the company can provide direct services if needed (e.g., assist in using the home device, report the frequency of usage, coordinate replacement of devices in case of a technical problems, etc.)
• •11. Agree to be examined by an ophthalmologist if SE shows symptoms of changes during the study
• •12. Have a US address and do not plan on traveling abroad during the study period
• •13. Fluent in English
• •14. Perform a reliable ForeseeHome test during the enrollment visit